Investigating predictors of progression from mild cognitive impairment to Alzheimer’s disease based on different time intervals

Author:

Wu Yafei12,Wang Xing12,Gu Chenming12,Zhu Junmin12,Fang Ya123ORCID

Affiliation:

1. Xiamen University School of Public Health, , Xiamen, Fujian , China

2. Key Laboratory of Health Technology Assessment of Fujian Province , Xiamen University, Xiamen, Fujian , China

3. Xiamen University National Institute for Data Science in Health and Medicine, , Xiamen, Fujian , China

Abstract

Abstract Background Mild cognitive impairment (MCI) is the early stage of AD, and about 10–12% of MCI patients will progress to AD every year. At present, there are no effective markers for the early diagnosis of whether MCI patients will progress to AD. This study aimed to develop machine learning-based models for predicting the progression from MCI to AD within 3 years, to assist in screening and prevention of high-risk populations. Methods Data were collected from the Alzheimer's Disease Neuroimaging Initiative, a representative sample of cognitive impairment population. Machine learning models were applied to predict the progression from MCI to AD, using demographic, neuropsychological test and MRI-related biomarkers. Data were divided into training (56%), validation (14%) and test sets (30%). AUC (area under ROC curve) was used as the main evaluation metric. Key predictors were ranked utilising their importance. Results The AdaBoost model based on logistic regression achieved the best performance (AUC: 0.98) in 0–6 month prediction. Scores from the Functional Activities Questionnaire, Modified Preclinical Alzheimer Cognitive Composite with Trails test and ADAS11 (Unweighted sum of 11 items from The Alzheimer’s Disease Assessment Scale-Cognitive Subscale) were key predictors. Conclusion Through machine learning, neuropsychological tests and MRI-related markers could accurately predict the progression from MCI to AD, especially in a short period time. This is of great significance for clinical staff to screen and diagnose AD, and to intervene and treat high-risk MCI patients early.

Funder

National Institute of Biomedical Imaging and Bioengineering

National Institute on Aging

National Institutes of Health

Alzheimer's Disease Neuroimaging Initiative

National Key R&D Program of China

National Natural Science Foundation of China

Publisher

Oxford University Press (OUP)

Subject

Geriatrics and Gerontology,Aging,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3